Skip to main content

Table 3 Clinical, anatomic, and hemodynamic characteristics according to the presence of genetic variant

From: Genetic relevance and determinants of mitral leaflet size in hypertrophic cardiomyopathy

 

No pathogenic or likely pathogenic variant group (n = 110)

1Only mitochondria related nDNA or mtDNA variant group (n = 33)

1Only sarcomere gene variant group (n = 58)

1Both sarcomere and mitochondria-related gene variant group (n = 9)

§P

Age, years

61.1 ± 12.9

61.5 ± 12.3

54.4 ± 14.7**, †

57.0 ± 11.8

0.014

Women, n (%)

31 (28)

6 (18)

21 (36)

4 (44)

0.227

Hypertension, n (%)

69 (63)

21 (64)

26 (45)

2 (22)

0.019

Diabetes, n (%)

21 (19)

6 (18)

10 (17)

2 (22)

0.982

Body surface area, m2

1.78 ± 0.21

1.79 ± 0.20

1.77 ± 0.19

1.70 ± 0.11

0.679

FHx of SCD-1st, n (%)

6 (6)

2 (6)

5 (9)

1 (11)

0.820

Syncope, n (%)

3 (3)

1 (3)

5 (9)

1 (11)

0.270

5-year SCD risk, % (n = 123)

2.01 ± 1.72

2.02 ± 1.45

2.73 ± 1.58*

2.10 ± 0.97

0.163

Echocardiography and CMR

 ApHCM, n (%)

57 (52)

22 (67)

19 (33)

2 (22)

0.004

 LVOT PPG (rest), mmHg

17.4 ± 26.5

8.0 ± 7.4*

10.5 ± 11.9

5.2 ± 2.1

0.005

 LVOT PPG (Valsalva), mmHg

31.2 ± 40.7

17.4 ± 23.4

18.5 ± 21.1*

6.2 ± 2.9

0.025

 Dynamic obstruction, n (%)

31 (28)

5 (15)

13 (22)

0 (0)

0.142

 LVEDV, mL

66.8 ± 22.5

66.2 ± 20.6

69.9 ± 27.1

71.3 ± 34.1

0.730

 LVESV, mL

22.5 ± 8.4

24.8 ± 9.9

24.6 ± 10.2

29.2 ± 20.3

0.145

 LA volume index, mL/m2

35.2 ± 14.9

31.8 ± 11.1

40.6 ± 22.9†

43.6 ± 15.7

0.051

 MR grade

0.49 ± 0.28

0.40 ± 0.21

0.52 ± 0.36

0.56 ± 0.17

0.217

 LV ejection fraction, %

65.7 ± 5.0

62.5 ± 7.6*

64.3 ± 6.9

61.2 ± 8.7*

0.021

 s′, cm/s

6.8 ± 1.7

6.9 ± 2.1

6.6 ± 1.7

7.0 ± 1.4

0.748

 E/e′

14.8 ± 5.5

13.9 ± 5.3

15.6 ± 6.9

13.5 ± 4.6

0.462

 Maximal thickness, mm

18.7 ± 3.6

18.1 ± 2.6

19.6 ± 3.8†

19.8 ± 3.5

0.164

 LV mass index by CMR, g/m2 (n = 132)

85.1 ± 23.9

84.3 ± 24.3

88.5 ± 22.0

84.7 ± 15.9

0.885

AML lengths

 AML-PLX, mm

32.4 ± 4.5

32.5 ± 4.3

31.7 ± 4.7

29.7 ± 3.7

0.260

 AML-3CH, mm

28.2 ± 3.5

27.7 ± 3.0

28.8 ± 3.9

28.4 ± 4.3

0.633

 AML-average, mm

30.2 ± 3.6

30.2 ± 3.2

30.3 ± 3.9

29.1 ± 3.6

0.834

 iAML-PLX, mm/m2

18.4 ± 2.7

18.4 ± 2.9

18.0 ± 2.9

17.5 ± 2.1

0.671

 iAML-3CH, mm/m2

16.1 ± 2.4

15.7 ± 1.9

16.4 ± 2.4

16.8 ± 2.5

0.408

 iAML-average, mm/m2

17.2 ± 2.3

17.0 ± 2.2

17.2 ± 2.4

17.1 ± 2.1

0.981

  1. One patient with pathogenic variants in GAA was excluded. 1Pathogenic or likely pathogenic mutation or damaging mtDNA variant; §p, p-value for ANOVA. *p < 0.05, **p < 0.01 versus no pathogenic or likely pathogenic variant group; p < 0.05 versus mitochondrial related variant group; See abbreviations in Table 1